Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | ProCAID: Investigating the use of AZD5363 alongside chemotherapy in mCRPC

Simon Crabb • 15 Feb 2019
GU Cancers 2019
Genitourinary Cancer Prostate Cancer Capivasertib Docetaxel
ProCAID

Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, discusses results from the Phase II ProCAID trial (NCT02121639), investigating the efficacy of AZD5363 combined with docetaxel in treating metastatic castration-resistant prostate cancer (mCRPC). This interview took place at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Simon Crabb

1:25
ProCAID: capivasertib plus docetaxel and prednisolone chemotherapy for the treatment of mCRPC
Simon Crabb • 19 Feb 2022
0:50
Maintenance therapy for patients with advanced urothelial carcinoma
Simon Crabb • 19 Feb 2022
1:36
ATLANTIS rucaparib arm: maintenance PARPi following chemotherapy for mUC
Simon Crabb • 19 Feb 2022
1:35
PARP inhibitors for the treatment of metastic castration-resistant prostate cancer
Simon Crabb • 19 Feb 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals